Demographics in patients with graft rejection and febrile controls
| Demographics . | All patients (n = 22) . | Graft rejection (n = 7) . | Febrile controls (n = 15) . | P . |
|---|---|---|---|---|
| Age at HCT, y | .33 | |||
| 0-10 | 45.5% (n = 10) | 28.5% (n = 2) | 53.5% (n = 8) | |
| 10-20 | 50% (n = 11) | 57% (n = 4) | 46.5% (n = 7) | |
| >20 | 4.5% (n = 1) | 14.5% (n = 1) | None | |
| Sex | 1 | |||
| Female | 45.5% (n = 10) | 43% (n = 3) | 46.5% (n = 7) | |
| Male | 54.5% (n = 12) | 57% (n = 4) | 53.5% (n = 8) | |
| Race | .05 | |||
| Caucasian | 73% (n = 16) | 43% (n = 3) | 86.5% (n = 13) | |
| African American | 27% (n = 6) | 57% (n = 4) | 13.5% (n = 2) | |
| Diagnosis | .33 | |||
| Severe aplastic anemia | 50% (n = 11) | 57% (n = 4) | 46.5% (n = 7) | |
| Fanconi anemia | 45.5% (n = 10) | 28.5% (n = 2) | 53.5% (n = 8) | |
| Genetically undefined chromosomal fragility syndrome | 4.5% (n = 1) | 14.5% (n = 1) | None | |
| Conditioning | .82 | |||
| Bu/Cy/Flu/ATG | 50% (n = 11) | 43% (n = 3) | 53.5% (n = 8) | |
| Alem/Flu/Mel | 36.5% (n = 8) | 57% (n = 4) | 26.5% (n = 4) | |
| Bu/Cy/ATG | 4.5% (n = 1) | None | 6.67% (n = 1) | |
| Cy/ATG | 4.5% (n = 1) | None | 6.67% (n = 1) | |
| Flu/Mel | 4.5% (n = 1) | None | 6.67% (n = 1) | |
| Graft | 1 | |||
| PBSC | 82% (n = 18) | 85.5% (n = 6) | 80% (n = 12) | |
| Bone marrow | 18% (n = 4) | 14.5% (n = 1) | 20% (n = 3) | |
| GVHD prophylaxis | .26 | |||
| Ex vivo T-cell depletion | 82% (n = 18) | 100% (n = 7) | 73.5% (n = 11) | |
| CSA-based regimen | 18% (n = 4) | None | 26.5% (n = 4) |
| Demographics . | All patients (n = 22) . | Graft rejection (n = 7) . | Febrile controls (n = 15) . | P . |
|---|---|---|---|---|
| Age at HCT, y | .33 | |||
| 0-10 | 45.5% (n = 10) | 28.5% (n = 2) | 53.5% (n = 8) | |
| 10-20 | 50% (n = 11) | 57% (n = 4) | 46.5% (n = 7) | |
| >20 | 4.5% (n = 1) | 14.5% (n = 1) | None | |
| Sex | 1 | |||
| Female | 45.5% (n = 10) | 43% (n = 3) | 46.5% (n = 7) | |
| Male | 54.5% (n = 12) | 57% (n = 4) | 53.5% (n = 8) | |
| Race | .05 | |||
| Caucasian | 73% (n = 16) | 43% (n = 3) | 86.5% (n = 13) | |
| African American | 27% (n = 6) | 57% (n = 4) | 13.5% (n = 2) | |
| Diagnosis | .33 | |||
| Severe aplastic anemia | 50% (n = 11) | 57% (n = 4) | 46.5% (n = 7) | |
| Fanconi anemia | 45.5% (n = 10) | 28.5% (n = 2) | 53.5% (n = 8) | |
| Genetically undefined chromosomal fragility syndrome | 4.5% (n = 1) | 14.5% (n = 1) | None | |
| Conditioning | .82 | |||
| Bu/Cy/Flu/ATG | 50% (n = 11) | 43% (n = 3) | 53.5% (n = 8) | |
| Alem/Flu/Mel | 36.5% (n = 8) | 57% (n = 4) | 26.5% (n = 4) | |
| Bu/Cy/ATG | 4.5% (n = 1) | None | 6.67% (n = 1) | |
| Cy/ATG | 4.5% (n = 1) | None | 6.67% (n = 1) | |
| Flu/Mel | 4.5% (n = 1) | None | 6.67% (n = 1) | |
| Graft | 1 | |||
| PBSC | 82% (n = 18) | 85.5% (n = 6) | 80% (n = 12) | |
| Bone marrow | 18% (n = 4) | 14.5% (n = 1) | 20% (n = 3) | |
| GVHD prophylaxis | .26 | |||
| Ex vivo T-cell depletion | 82% (n = 18) | 100% (n = 7) | 73.5% (n = 11) | |
| CSA-based regimen | 18% (n = 4) | None | 26.5% (n = 4) |
Percentages were rounded to nearest 0.5 or 0.01 to a sum of 100%. Alem, alemtuzumab; ATG, antithymocyte globulin; Bu, busulfan; CSA, cyclosporine; Cy, cyclophosphamide; Flu, fludarabine; GVHD, graft-versus-host disease; Mel, melphalan.